Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Bullboard - Stock Discussion Forum Concordia Healthcare Corp. T.CXR.R

TSX:CXR.R - Post Discussion

Concordia Healthcare Corp. > RBC lowered this week $14 to $10USD still outperform
View:
Post by cg16 on Nov 05, 2016 3:27pm

RBC lowered this week $14 to $10USD still outperform

Yes Rye I read it. 
rev $204.4M vs Scotia $203M ($58M US biz)
adj ebitda $119.6M vs Scotia $115M 
adj EPS $0.94  vs Scotia $0.91 

Longs should expect headline to be "CXR misses" because the concensus is made up of many lazy Analysts that just look at guidance and divide by 4.  
Concensus is $207.1M, $122.7M, $1.04
Comment by LongTermLong on Nov 05, 2016 3:34pm
This post has been removed in accordance with Community Policy
Comment by SteadyHandsStan on Nov 05, 2016 3:56pm
LongTermLong, They reduced Friday late afternoon.  If you are not a RBC client and you do not get these reports, please don't shout out that information is incorrect.  I did a cut and paste of the new target $10 and the research update in my previous post.  CHILL. 
Comment by LongTermLong on Nov 05, 2016 4:34pm
This post has been removed in accordance with Community Policy
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities